H

ello, everyone, and how are you today? A warm and shiny sun is enveloping the Pharmalot campus this morning, where things have quieted down now that the shortest of short people has left for the schoolhouse and the official mascots are happily snoozing in their recliners. As for us, we are busy foraging for interesting items and, of course, quaffing some cups of stimulation. Feel free to join in. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch …

Gilead Sciences (GILD) won FDA approval of a CAR-T treatment for advanced lymphoma, only the second such medicine approved in the U.S., STAT says. The endorsement validates the $11 billion bet Gilead made recently by buying Kite Pharma, which developed the drug, but also accelerates debate about drug costs, since Gilead will charge $373,000 for a one-time dose for Yescarta. Nonetheless, the approval helps Gilead diversify, which investors have demanded.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy